Clinical trials: Venous Embolism
Venous Thromboembolism
Statin Use in Patients With Acute VTE
This is a pilot, randomized, open-labelled study. Eligible patients will be enrolled and randomized 1:1 into "anticoagulation" arm or "anticoagulation plus atorvastatin" arm, with atorvastatin given at 40 mg orally daily for 3…
- Trial name
- NCT02331095
- Testing
- Atorvastatin, Anticoagulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University
Pain, Deep Venous Thrombosis
EVENT: Hydrotherapy and Deep Venous Thrombosis
The main objective of this study is to demonstrate that hydrotherapy in a specific place can reduce the risk of post-thrombotic syndrome.
- Trial name
- NCT00348907
- Testing
- thermal cure, late thermal cure
- Where
- 27 sites in France
- Volunteers
- 3 people
- Sponsor
- Association Francaise pour la Recherche Thermale
Retinal Vein Occlusion
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
- Trial name
- NCT00403039
- Testing
- Ranibizumab (Lucentis )
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MAGNOLIA (NCT05171075)
- Testing
- Abelacimab, Dalteparin
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 417 people
- Sponsor
- Anthos Therapeutics, Inc.
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Venous Thromboembolism, Deep Vein Thrombosis
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
The rates of Venous thromboembolism (VTE) after orthopedic surgery are as high as 40-60% without prophylactic measures. Enoxaparin, a low-molecular-weight heparin, produces an anticoagulant effect by binding antithrombin, thereby…
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolus
- Trial name
- NCT03339349
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
Venous Thromboembolism, Pulmonary Embolism
Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, DVT
- Trial name
- NCT05264168
- Testing
- Rivaroxaban, Apixaban
- Where
- United States
- Volunteers
- 41,875 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04735523
- Testing
- Dabigatran, Warfarin
- Where
- United States
- Volunteers
- 5,350 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism
High-Risk Factors for VTE Death
Study population and characteristics This retrospective cohort study initially screened 105,168 consecutive hospitalized patients at Shihezi People's Hospital from February 2022 to June 2025.
- Trial name
- NCT07767279
- Testing
- comorbidity, Respiratory Failure, Sepsis
- Where
- China
- Volunteers
- 105,168 people
- Sponsor
- China International Neuroscience Institution
Myotonic Dystrophy 1
Venous Thromboembolism in Myotonic Dystrophy Type 1
Investigators identified a high risk of deep vein thrombosis and pulmonary embolism in patients presenting myotonic dystrophy type 1 treated in our hospital, 10 times higher than general population matched on age and sex.
- Trial name
- DM1-VTE (NCT03424460)
- Testing
- Haemostasis tests, Monocytes and megacaryocytes culture and RNA extraction, RNA extraction
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism
the Effectiveness of Different Risk Scales In Predicting VTE in Respiratory Inpatients
To compare the predictive effectiveness of the Caprini risk assessment model, the Padua risk assessment model and the VTE risk assessment in medical patients mentioned in the 2018 edition of the Guidelines for the diagnosis…
- Trial name
- NCT04963374
- Testing
- risk evolution scale
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO)
Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases
The study compares the perceived treatment burden in patients undergoing intravitreal anti-VEGF treatment for either wet age related macular degeneration, macular edema after retinal vein occlusions or diabetic macular edema.
- Conditions
- Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME)
- Trial name
- NCT07514559
- Where
- Austria
- Volunteers
- 393 people
- Sponsor
- Hospital Hietzing
Venous Thromboembolism, Pulmonary Embolism
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening.
- Trial name
- PHACS (NCT00876915)
- Testing
- dalteparin injection
- Where
- 7 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- University of Rochester
Venous Thromboses, Venous Disease
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for…
- Conditions
- Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
- Trial name
- NCT05409976
- Testing
- GORE® VIAFORT Vascular Stent
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 136 people
- Sponsor
- W.L.Gore & Associates
Venous Thromboembolism, Anticoagulant
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal…
- Conditions
- Venous Thromboembolism, Anticoagulant, Elderly
- Trial name
- Jason (NCT04257487)
- Testing
- Sulodexide
- Where
- Italy
- Volunteers
- 1,455 people
- Sponsor
- Arianna Anticoagulazione Foundation
Cerebral Venous Thrombosis
Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis
This study aims to evaluate the efficacy and safety of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, combined with standard anticoagulant therapy compared with standard anticoagulant therapy alone in patients with…
- Trial name
- NCT07801638
- Testing
- Tocilizumab, Standard Treatment
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Capital Medical University
Atrial Fibrillation, Venous Thromboses
Pharmacogenetic Dosage Algorithm for Acenocoumarol
The use of coumarins has been a challenge for doctors because of its narrow therapeutic range and they show great inter and intra-individual variability in the dose necessary to achieve an international normalized ratio (INR)…
- Conditions
- Atrial Fibrillation, Venous Thromboses, Cardiac Valve Disease
- Trial name
- NCT03015025
- Testing
- Acenocoumarol
- Where
- Spain
- Volunteers
- 340 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
DVT - Deep Vein Thrombosis
Predictive Value of Modified Caprini Score and D-Dimer in Managing Lower Limb Venous Thrombosis in Cardiothoracic Patients
The goal of this observational study is to evaluate the predictive efficacy of the Modified Caprini Risk Assessment Score and D-Dimer in identifying and managing lower extremity venous thrombosis (LEVT) among cardiothoracic…
- Trial name
- DVT (NCT06729021)
- Testing
- GCS, LMWH
- Where
- Iraq
- Volunteers
- 112 people
- Sponsor
- Al-Nahrain University
Deep Vein Thrombosis, Pulmonary Embolism
D-Dimer and IPG for Recurrent Thrombosis (DIRECT)
To simplify and improve the diagnostic approach to patients with clinically suspected recurrent DVT by determining whether the results of the combination of IPG and d-dimer testing, using a whole blood agglutination assay, can be…
- Trial name
- NCT00182247
- Testing
- venogram
- Where
- 8 sites in Canada, Italy
- Volunteers
- 600 people
- Sponsor
- Hamilton Health Sciences Corporation
Pulmonary Embolus/Emboli, Thromboembolism, Pulmonary
Venous Phase Dual Energy CT in Patients Suspected for Pulmonary Embolism.
Venous phase spectral or dual energy (DE) chest computed tomography (CT) in patients with suspected pulmonary embolism (PE) compared to standard computed tomography pulmonary angiography (CTPA): sensitivity, evaluation of iodine…
- Trial name
- NCT04859478
- Testing
- Dual energy / spectral portal venous chest computed tomography
- Where
- 2 sites in Denmark
- Volunteers
- 160 people
- Sponsor
- Copenhagen University Hospital at Herlev